Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Stock Has Average Price Target of $37.33 According to Brokerages

Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) have been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $37.33.

Several analysts have issued reports on ELOX shares. Leerink Partners set a $32.00 price objective on shares of Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, September 18th. Lucid Cap Mkts upgraded Eloxx Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 20th. Lifesci Capital assumed coverage on Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price objective on the stock. Guggenheim cut their price objective on Eloxx Pharmaceuticals from $43.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, October 28th. Finally, Weiss Ratings assumed coverage on Eloxx Pharmaceuticals in a research report on Friday, August 14th. They issued a “sell (d)” rating on the stock.

Eloxx Pharmaceuticals Trading Down 2.8%

Eloxx Pharmaceuticals stock opened at $12.44 on Friday. Eloxx Pharmaceuticals has a twelve month low of $8.20 and a twelve month high of $23.40. The stock has a market capitalization of $50.21 million, a price-to-earnings ratio of -8.08 and a beta of -1,918.69. The stock has a 50 day moving average of $14.72 and a two-hundred day moving average of $13.71.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter. Equities analysts predict that Eloxx Pharmaceuticals will post -2.61 earnings per share for the current year.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation therapy, an approach intended to encourage cells to read through certain genetic mutations and restore production of functional proteins.

The company’s lead investigational product was ELX-02, a synthetic aminoglycoside designed to promote readthrough of nonsense mutations while seeking to limit the toxicity associated with older aminoglycoside compounds.